BrMets was 23% higher ($184,872 vs. $150,931; pϭ0.010) after adjustment for other factors. The difference was consistent across resources: 25% higher hospitalization costs $46,871 vs. $37,504; pϭ.082); 23% higher ambulatory costs, ($121,224 vs. $98,276; pϭ0.033); 23% higher retail pharmacy costs, ($13,282 vs. $10,774; pϭ0.118). Patients with BrMets averaged more hospitalizations (2.4 vs. 1.9; pϭ0.005), ER visits (2.7 vs. 2.2; pϭ0.067), and ambulatory encounters (111 vs. 92; pϭ0.005) from initial NSCLC diagnosis to end of follow-up. CONCLUSIONS: Intensity of resource use and costs were higher in metastatic NSCLC, especially in BrMets patients. Treatment that improves disease control could reduce the intensity of cost and resource use among NSCLC BrMets patients.
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Institut Curie, Paris, France, 2 Centre Léon Bérard, Lyon , France, 3 StatProcess, Port-Mort, France, 4 CLCC Oscar Lambret, Lille, France, 5 CLCC François Baclesse, Caen, France, 6 Centre René Huguenin, Saint Cloud, France, 7 Institut Bergonié, Bordeaux, France, 8 CRLCC Henri Becquerel, Rouen, France, Dijon, France, 10 Centre d'Oncologie de Gentilly, Nancy, France, 11 Clinique Sainte Catherine, Avignon, France, 12 GlaxoSmithKline, Marly le Roi, France, 13 Céri Médical, Garches, France, 14 Hôpital Henri Mondor, Créteil, France OBJECTIVES: Incidence of breast cancer (BC) with brain metastases (BM) is increasing especially among patients with HER2-positive status. Their management is based on diversified and expensive treatments for which costs data are scarce. We estimated hospital costs of BCBM and their evolution within a period of two years following BM diagnosis. METHODS: An observational retrospective multicenter study was conducted on 207 HER2ϩ breast cancer (BC) patients, newly diagnosed with brain metastases (BM) as first site of relapse or secondary metastases between January 2006 and December 2008. Data on patient profile, treatments (neurosurgery, radiotherapy, chemotherapy), complications leading to rehospitalisation and hospitalisation stays were collected. Direct medical costs were estimated from the Health Insurance perspective using Diagnosis Related Groups (DRGs) official tariffs and expensive drugs tariffs (2007) . Censored treatment cost data were analyzed using the Bang and Tsiasis method. RESULTS: Patients were treated by radiation therapy (91.8%), chemotherapy (84.5%) and neurosurgery (12.6%). The mean cost of management of HER2-positive BCBMs was 18,480€/patient from 0-6 months, 16,306€ from 7-12 months, 15,844€ from 13-18 months and 15,225€ from 19-24 months. The mean cost of the first year following diagnosis was 33,847€/patient. The proportion of costs attributed to inpatient hospitalizations stay was equal to the one attributed to expensive drugs whatever the time period of follow-up (17,153€/patient for hospitalizations vs 16,693€/patient for expensive drugs after one year of follow-up). Patients with BM as first site of relapse induced more health care resources compared to patients with secondary BM. CONCLUSIONS: The management of BCBM generates important health care resources mainly concentrated within the first months. Health care costs decrease during the follow-up period while the variability of costs is increasing. These results illustrate the personalized disease management at the advanced stage of disease. Observational studies are an interesting opportunity to estimate health care resources and associated costs more precisely.
PCN42 TREATMENT COSTS OF BONE METASTASES IN PATIENTS WITH LUNG CANCER: RESULTS FROM A FRENCH PROSPECTIVE, OBSERVATIONAL, MULTICENTER STUDY (GFPC 0601)
Borget I 1 , Decroisette C 2 , David P 3 , Fournel P 4 , Locher C 5 , Grangeon V 6 , Thomas P 7 , Barlesi F 8 , Bombaron P 9 , Chouaid C 10 
OBJECTIVES:
The aim of this prospective, observational, multicenter study was to estimate the management costs of bone metastatic disease (BMD) in patients with lung cancer. METHODS: Consecutive patients presenting BMD from lung cancer diagnosed between May 2006 and May 2007 in 40 centers were enrolled. The natural course of bone metastatic disease was modeled using a Markov model with 4 health states (asymptomatic patient, symptomatic patient, skeletal-related event (SRE) and death) and a cycle length of one month, until death or a 5-year period. Direct medical costs induced by BMD (including symptomatic or therapeutic treatment and hospitalizations) were prospectively collected from the health care provider's perspective. RESULTS: Among the 554 patients enrolled (mean age 62 years, 77% of males), 26.7% presented a SRE at diagnosis and 39% during follow-up. The median survival time was 5.8 months, and the 1-and 2-year survival rates were 22% and 7%, respectively. The main BMD treatments were opiate therapy (78%), biphosphonates (52%), radiotherapy (42%), and surgery (9%). The mean monthly BMD treatment costs were 190 €, 374 €, and 4 672 € for asymptomatic patients, symptomatic patients, and patients with SRE, respectively. The average first-year BMD management cost was 3 999 € Ϯ 4 135 (IC95%: 374-15 886), and 49.5% of this cost was attributable to patients with SRE. CONCLUSIONS: This analysis underlines the burden of bone metastatic disease, and particularly of skeletal-related event in overall treatment costs. 
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COST OF HPV ASSOCIATED DISEASES IN SAINT-PETERSBURG
OBJECTIVES:
To assess an economical burden of HPV associated diseases in Saint-Petersburg. METHODS: Total lifetime costs (direct and indirect) of HPV-associated diseases (cervical cancer, cervical dysplasia -CIN I-III, and condylomatosisgenital warts) in one cohort (13 years old girls in 2010; life expectancy -74 years; cohort amount -16 thousands) were estimated. Epidemiologic forecast was prepared based on mathematical-statistical modeling with least-square method of regression analysis on parent observation matrix. Raw epidemiologic data on morbidity and mortality were derived from official statistics. Cost of treatment was calculated using current out-patient and hospital tariffs (in obligatory medical insurance program) and standards of treatment (as of 2009). Indirect costs (gross output underproduction, disability pension, sick-pay etc.) were assessed based on existing legislation (Federal and Saint-Petersburg's regional). No discounting was applied in the analysis. RESULTS: Rates (per 100 000 female population) of dysplasia, genital warts, and cervical cancer incidence, and death were 16.5, 38.7-59,7, and 13.1-17.3, and 7.1-9.6, respectively. 10 years' growth of cervical cancer incidence and mortality was expected to be 12-15% and 8-15% (in different age groups), respectively. Total annual economic burden due to HPV diseases was 822 mln. Rub which includes: 72 mln. Rub -treatment of cervical cancer, 637 mln. Rub -indirect costs due to cervical cancer; 89 mln. Rub -dysplasia, 20 mln. Rub -genital warts. Sum of total cost in one cohort was 1.1 billion Rub. CONCLUSIONS: Economic burden of HPV-associated diseases in Saint-Petersburg in one cohort expected to be 1.1 billon Rub.
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COST-OF-ILLNESS STUDY OF HUMAN PAPILLOMAVIRUS CANCERS IN ENGLAND
Tempest MJ 1 , Thurston S 1 , Carroll S 2 , Charman F 2 , Rajoriya F 2 1 Pharmerit Ltd, York, UK, 2 Sanofi Pasteur MSD, Maidenhead, UK BACKGROUND: Human papillomavirus (HPV) is the most common sexually transmitted infection and is a well-established cause of anogenital cancers (responsible for over 70% of cervical cancers). Vaccines that target the HPV strains responsible for such cancers elicit virus-neutralising antibody responses, thus preventing the initial infection and some re-infections associated with the same HPV types. Research also suggests that HPV is a risk factor in cancers originating in the upper aero-digestive tract, known as head and neck (HϩN) cancers. OBJECTIVES: To estimate the prevalence, incidence and associated costs of HPV-related anogenital and HϩN cancers in England. METHODS: The Hospital Episode Statistics (HES) database was used to estimate the prevalence and incidence of anogenital and head and neck cancers in England from 2002 to 2011. An in-house epidemiologic study and published sources were used to estimate the proportions of these cancers attributable to HPV . Cost estimates using Healthcare Resource Groups (HRGs) in combination with the most recent UK National Tariff will be applied to the data. Estimates for costs outside the scope of the National Tariff (such as rehabilitation costs which, for example, are a key component of HϩN cancer treatment pathways) will be derived from expert opinion using resource use surveys. Results will be validated by clinical experts in each cancer included in the analysis. RESULTS: The analyses will highlight key areas of the broader burden of HPV-related cancers and quantify the associated healthcare costs falling on the NHS in England. A proportion of HPV-related cancers can be prevented through vaccination, as such, the analysis aims to capture overall costs and, in turn, the potential for cost offsets through the implementation of preventative healthcare pathways. CONCLUSIONS: The use of HPV vaccines has the potential to reduce the incidence of a proportion of HPV-related cancers, improving patient quality of life in a cost-effective manner.
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